> Details

Tribian, Laura Sophie; Lennartz, Maximilian; Höflmayer, Doris; de Wispelaere, Noémi; Dwertmann Rico, Sebastian; von Bargen, Clara; Kind, Simon; Reiswich, Viktor; Viehweger, Florian; Lutz, Florian; Bertram, Veit; Fraune, Christoph; Gorbokon, Natalia; Weidemann, Sören; Hube-Magg, Claudia; Menz, Anne; Uhlig, Ria; Krech, Till; Hinsch, Andrea; Burandt, Eike; Sauter, Guido; Simon, Ronald; Kluth, Martina; Steurer, Stefan; [...]

Diagnostic Role and Prognostic Impact of PSAP Immunohistochemistry: A Tissue Microarray Study on 31,358 Cancer Tissues

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Diagnostic Role and Prognostic Impact of PSAP Immunohistochemistry: A Tissue Microarray Study on 31,358 Cancer Tissues
  • Contributor: Tribian, Laura Sophie; Lennartz, Maximilian; Höflmayer, Doris; de Wispelaere, Noémi; Dwertmann Rico, Sebastian; von Bargen, Clara; Kind, Simon; Reiswich, Viktor; Viehweger, Florian; Lutz, Florian; Bertram, Veit; Fraune, Christoph; Gorbokon, Natalia; Weidemann, Sören; Hube-Magg, Claudia; Menz, Anne; Uhlig, Ria; Krech, Till; Hinsch, Andrea; Burandt, Eike; Sauter, Guido; Simon, Ronald; Kluth, Martina; Steurer, Stefan; [...]
  • Published: MDPI AG, 2023
  • Published in: Diagnostics, 13 (2023) 20, Seite 3242
  • Language: English
  • DOI: 10.3390/diagnostics13203242
  • ISSN: 2075-4418
  • Keywords: Clinical Biochemistry
  • Origination:
  • Footnote:
  • Description: Prostate-specific acid phosphatase (PSAP) is a marker for prostate cancer. To assess the specificity and prognostic impact of PSAP, 14,137 samples from 127 different tumor (sub)types, 17,747 prostate cancers, and 76 different normal tissue types were analyzed via immunohistochemistry in a tissue microarray format. In normal tissues, PSAP staining was limited to the prostate epithelial cells. In prostate cancers, PSAP was seen in 100% of Gleason 3 + 3, 95.5% of Gleason 4 + 4, 93.8% of recurrent cancer under androgen deprivation therapy, 91.0% of Gleason 5 + 5, and 31.2% of small cell neuroendocrine cancer. In non-prostatic tumors, PSAP immunostaining was only found in 3.2% of pancreatic neuroendocrine tumors and in 0.8% of diffuse-type gastric adenocarcinomas. In prostate cancer, reduced PSAP staining was strongly linked to an advanced pT stage, a high classical and quantitative Gleason score, lymph node metastasis, high pre-operative PSA levels, early PSA recurrence (p < 0.0001 each), high androgen receptor expression, and TMPRSS2:ERG fusions. A low level of PSAP expression was linked to PSA recurrence independent of pre- and postoperative prognostic markers in ERG-negative cancers. Positive PSAP immunostaining is highly specific for prostate cancer. Reduced PSAP expression is associated with aggressive prostate cancers. These findings make PSAP a candidate marker for prognostic multiparameter panels in ERG-negative prostate cancers.
  • Access State: Open Access